In 2019, the American Society for Gastrointestinal Endoscopy (ASGE) published revised guidelines that attempted to risk stratify the likelihood of choledocholithiasis based on clinical predictors including age, LFT derangement, total bilirubin, presence of cholangitis, imaging reporting a dilated CBD or the presence of choledocholithiasis. The gene discussed is OPN1MW; the disease is choledocholithiasis.